In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (NASDAQ: URGN). The company’s shares opened today at $46.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.4% and a 46.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Urogen Pharma Ltd is a Strong Buy with an average price target of $73.67.
See today’s analyst top recommended stocks >>
Based on Urogen Pharma Ltd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.38 million. In comparison, last year the company had a GAAP net loss of $6.2 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.
